Epigral Q1FY27 PAT up 25% to ₹99 Cr; ₹600 Cr Capex for Epoxy Resin Plant

Epigral Limited announced its un-audited financial results for Q1 FY27, reporting a 25% year-on-year increase in Profit After Tax (PAT) to ₹99 crore, up from ₹79 crore in Q1 FY26. Quarterly revenue grew by 15% to ₹709 crore from ₹615 crore in the prior year period. The company's board also approved a significant capital expenditure of approximately ₹600 crore for entering the Epoxy Resin and Formulations business, including setting up a Multi-Purpose Plant (MPP). This strategic expansion aims to leverage internal raw material sourcing, particularly Epichlorohydrin (ECH) and Caustic Soda, for advanced materials and specialty chemicals. The commercial plant is expected to be commissioned in H2FY28, with a pilot plant operational by Q2FY27.